PMID- 9183812
OWN - NLM
STAT- MEDLINE
DCOM- 19970801
LR  - 20161124
IS  - 0887-4476 (Print)
IS  - 0887-4476 (Linking)
VI  - 26
IP  - 3
DP  - 1997 Jul
TI  - NMDA receptors in nucleus accumbens modulate stress-induced dopamine release in 
      nucleus accumbens and ventral tegmental area.
PG  - 225-34
AB  - Converging evidence suggests that dopamine (DA) transmission in nucleus accumbens 
      (NAcc) is modulated locally by an excitatory amino acid (EAA)-containing input 
      possibly originating in medial prefrontal cortex (PFC). In the present study, we 
      examined the effects of intra-NAcc administration of EAA receptor antagonists on 
      stress-induced increases of NAcc DA levels and of dendritically released DA in 
      the ventral tegmental area (VTA). Local injection of the NMDA receptor 
      antagonist-AP-5 (0.05, 0.5, and 5.0 nmoles)-dose-dependently potentiated 
      increases in NAcc DA levels elicited by 15 min of restraint stress. In contrast, 
      local application of equivalent doses of the kainate/AMPA receptor 
      antagonist-DNQX-failed to alter the NAcc DA stress response reliably. In a 
      separate experiment, we found that intra-NAcc injection of AP-5 also potentiated 
      stress-induced increases in VTA DA levels. These results indicate that EAAs 
      acting at NMDA receptors in NAcc can modulate stress-induced DA release in this 
      region. Our data indicate, however, that this action exerts an inhibitory 
      influence on the NAcc DA stress response, suggesting that the relevant population 
      of NMDA receptors are not located on NAcc DA terminals. The fact that intra-NAcc 
      AP-5 injections also potentiated the DA stress response in VTA suggests instead 
      an action mediated by NMDA receptors located on NAcc neurons that feedback, 
      directly or indirectly, to cell bodies of the mesocorticolimbic DA system.
FAU - Doherty, M D
AU  - Doherty MD
AD  - Douglas Hospital Research Center, Department of Psychiatry, McGill University, 
      Verdun, Quebec, Canada.
FAU - Gratton, A
AU  - Gratton A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Synapse
JT  - Synapse (New York, N.Y.)
JID - 8806914
RN  - 0 (Excitatory Amino Acid Antagonists)
RN  - 0 (Quinoxalines)
RN  - 0 (Receptors, N-Methyl-D-Aspartate)
RN  - 62T278S1MX (FG 9041)
RN  - 76726-92-6 (2-Amino-5-phosphonovalerate)
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
MH  - 2-Amino-5-phosphonovalerate/administration & dosage/pharmacology
MH  - Animals
MH  - Dopamine/*metabolism
MH  - Electrochemistry
MH  - Excitatory Amino Acid Antagonists/pharmacology
MH  - Male
MH  - Microinjections
MH  - Nucleus Accumbens/drug effects/*metabolism/*physiology
MH  - Quinoxalines/pharmacology
MH  - Rats
MH  - Receptors, N-Methyl-D-Aspartate/drug effects/*physiology
MH  - Stress, Psychological/*metabolism/*physiopathology
MH  - Ventral Tegmental Area/drug effects/*metabolism
EDAT- 1997/07/01 00:00
MHDA- 2000/06/20 09:00
CRDT- 1997/07/01 00:00
PHST- 1997/07/01 00:00 [pubmed]
PHST- 2000/06/20 09:00 [medline]
PHST- 1997/07/01 00:00 [entrez]
AID - 10.1002/(SICI)1098-2396(199707)26:3<225::AID-SYN4>3.0.CO;2-9 [pii]
AID - 10.1002/(SICI)1098-2396(199707)26:3<225::AID-SYN4>3.0.CO;2-9 [doi]
PST - ppublish
SO  - Synapse. 1997 Jul;26(3):225-34. doi: 
      10.1002/(SICI)1098-2396(199707)26:3<225::AID-SYN4>3.0.CO;2-9.